Estimated market cap $1.38BShares outstanding from the company’s latest SEC filing (all share classes, each priced at its own close; ADRs converted to ADS) × last close from Tiingo. Updated daily. This figure: shares as of Sep 16, 2026, last close Nov 13, 2026.29.90M shares, shares as of Sep 16, 2026CIK 1370053The SEC’s Central Index Key, the number it uses to identify every company and person that files.
Insider trades, 12 mo
0 buys · 41 sells
$9.50M sold, open market
Congress trades, 24 mo
—
No disclosed trades
13F holders
…
Lobbying, 12 mo
—
No lobbying filings
Federal contracts, 12 mo
—
None matched
Ask your AI:
Latest 10-Q
What changed in AnaptysBio, Inc.'s latest quarterly report, compared with the one before.
Loading…
Insider trades
Open-market trades from Form 4. 10b5-1 marks a plan set in advance.Open-market buys and sales by officers, directors and 10% owners, from SEC Form 4. A plan set in advance is marked 10b5-1.
Loading…
13F holders
Funds that report this stock, checked against market prices.Fund managers with over $100 million in US-listed stocks file a 13F each quarter, up to 45 days after quarter end. Long positions only.
Loading…
Top 10 holders.Premium lists every holder, with CSV downloads.
Disclosed in dollar ranges, up to 45 days after the trade.Members of Congress, their spouses and dependent children report trades in dollar ranges, up to 45 days after the trade.
Loading…
Lobbying
What AnaptysBio, Inc. and its lobbying firms report each quarter.A company that lobbies with its own staff reports its expenses; a lobbying firm it hires reports the income it received. We count both.
Loading…
Institutional ownership over time
How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.
Congress purchase Congress sale Insider sale over $1M
Adjusted for stock splits; not for dividends. The stock split 3-for-2 on Apr 20, 2026; earlier prices are shown divided by the split ratio. Where prices come from.
Live chart
Intraday and historical prices from TradingView. Quotes may be delayed.
Loading chart…
Information, not investment advice. Company matching is automatic; check the source before relying on one row.
13F holders, Q3 2026Fund managers with over $100 million in US-listed stocks file a 13F each quarter, up to 45 days after quarter end. Long positions only.
149
42.9% of shares · 55 added
Latest 10-Q
Q3 2026
What changed in AnaptysBio, Inc.'s latest quarterly report, compared with the one before.
Filed Nov 12, 2026 · Quarter ended Sep 30, 2026
Summary text goes here once it has loaded. Summary text goes here once it has loaded.
Summary text goes here once it has loaded.
Summary text goes here once it has loaded.
AI summary of changes vs the prior report. Written by AI from the paragraphs that changed, and checked against them. This is information, not investment advice.
Compared with the 10-KT for the period ended Jun 30, 2026. Sections compared: management's discussion, risk factors, legal proceedings and controls and procedures.
Open-market trades from Form 4. 10b5-1 marks a plan set in advance.Open-market buys and sales by officers, directors and 10% owners, from SEC Form 4. A plan set in advance is marked 10b5-1.
No open-market insider trades reported since Mar 30, 2026. Insiders have two business days to file.
Recent insider trades
How the stock has done since the trade date, measured against the S&P 500 over the same days. It describes the stock, not the trader's actual gain or loss.
149 funds report ANAB. Values checked against market prices.Fund managers with over $100 million in US-listed stocks file a 13F each quarter, up to 45 days after quarter end. Long positions only.
Funds report more than 100% of shares (Q2 2026)Fund managers with more than $100 million in US-listed stocks file a 13F each quarter. It lists their long stock positions only (shorts, options and bonds are left out) and can arrive up to 45 days after the quarter ends, so this is a snapshot of the quarter end. We add up the shares every fund reports in this class and divide by the shares outstanding. The total can pass 100%: the same shares are often reported by more than one manager (an adviser and the fund it runs), lent shares can be reported twice, and the share count can be out of date after buybacks. We divided 30.15M reported shares by 29.10M shares, from the company’s SEC filing as of Apr 23, 2026.
213 funds hold the stock.
Q3 2026: 43% · 5,560 of ~8,900 funds reported so farFunds have 45 days after a quarter ends to file. This quarter’s reports are still arriving, so the figure only counts the funds that have filed so far and will usually rise.
Q2 2025>100%
Q3 2025>100%
Q4 2025>100%
Q1 2026>100%
Q2 2026>100%
Q3 2026 (so far)43%
Q3 2026. 36 new, 55 added to, 41 trimmed, 102 exited since Q2 2026.
Download CSVEvery fund that holds ANAB, not only these ten. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Trades by members of Congress
Disclosed in dollar ranges, up to 45 days after the trade.Members of Congress, their spouses and dependent children report trades in dollar ranges, up to 45 days after the trade.
No recent congressional trades for this company.
Lobbying
What AnaptysBio, Inc. and its lobbying firms report each quarter.A company that lobbies with its own staff reports its expenses; a lobbying firm it hires reports the income it received. We count both.
No recent lobbying filings for this company.
Institutional ownership over time
How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.
Funds holding the stock
Shares they report, adjusted for splits
Funds holding the stock by quarter
Q1 2017
50
—
20.63M
$381.2M
Q2 2017
52
+2
20.56M
$328.0M
Q3 2017
71
+19
26.67M
$621.4M
Q4 2017
116
+45
35.66M
$2.4B
Q1 2018
134
+18
36.53M
$2.5B
Q2 2018
124
-10
37.56M
$1.8B
Q3 2018
129
+5
43.31M
$2.9B
Q4 2018
121
-8
43.84M
$1.9B
Q1 2019
129
+8
43.68M
$2.1B
Q2 2019
127
-2
45.44M
$1.7B
Q3 2019
119
-8
43.67M
$1.0B
Q4 2019
120
+1
42.74M
$463.1M
Q1 2020
116
-4
46.93M
$442.1M
Q2 2020
122
+6
45.17M
$672.7M
Q3 2020
132
+10
43.68M
$429.5M
Q4 2020
136
+4
42.00M
$602.0M
Q1 2021
122
-14
43.76M
$628.6M
Q2 2021
122
0
41.75M
$721.7M
Q3 2021
127
+5
41.42M
$748.8M
Q4 2021
136
+9
41.70M
$966.1M
Q1 2022
130
-6
44.40M
$733.0M
Q2 2022
124
-6
46.75M
$642.6M
Q3 2022
114
-10
48.84M
$830.6M
Q4 2022
118
+4
49.31M
$1.0B
Q1 2023
113
-5
47.00M
$681.7M
Q2 2023
116
+3
45.35M
$614.9M
Q3 2023
116
0
45.63M
$546.3M
Q4 2023
119
+3
46.20M
$659.7M
Q1 2024
133
+14
45.76M
$687.0M
Q2 2024
135
+2
44.71M
$746.9M
Q3 2024
160
+25
50.49M
$1.1B
Q4 2024
135
-25
53.13M
$468.9M
Q1 2025
153
+18
60.08M
$744.6M
Q2 2025
147
-6
55.15M
$816.2M
Q3 2025
166
+19
47.53M
$980.6M
Q4 2025
179
+13
44.03M
$1.4B
Q1 2026
209
+30
42.38M
$1.6B
Q2 2026
214
+5
30.15M
$2.1B
Q3 2026
149
-65
12.84M
$642.6M
Each point is a quarter-end, from Q1 2017 to Q3 2026. A fund's 13F lists its long positions in US-listed securities as of the last day of the quarter and arrives up to 45 days later, so each point shows holdings at quarter-end, not on the day they were reported.
Common shares only; options and bonds are left out. When a fund amends a report, the amended version is the one counted.
The history follows the company's current CUSIP number (032724106). If the company's shares were ever re-issued under a different CUSIP, the quarters before the change are not part of this series, so the first point (Q1 2017) can be later than the stock's first appearance in 13F reports.
Share counts are adjusted for stock splits (1.5-for-1 on Apr 20, 2026): reports from before a split are multiplied by its ratio, so every quarter is on the share count of Q3 2026.
A quarter appears once our daily update has built its summary. If a summary cannot be built, older reports are kept and the chart shows the quarters it has until the next update repairs it.